We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+39.37%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$191M
AUM Growth
+$41.4M
Cap. Flow
-$4.33M
Cap. Flow %
-2.27%
Top 10 Hldgs %
52.91%
Holding
54
New
5
Increased
14
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.3M
2
LOXO
Loxo Oncology, Inc
LOXO
+$2.88M
3
PRTA icon
Prothena Corp
PRTA
+$2.68M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.96M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$1.47M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$2.97M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.64M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$2.62M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.55M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 92.98%
2 Miscellaneous 7.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
26
CytomX Therapeutics
CTMX
$745M
$2.51M 1.31%
160,000
– –
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.59B
$2.48M 1.3%
35,000
-30,000
-46% -$1.91M
KA
28
DELISTED
Kineta, Inc. Common Stock
KA
$2.37M 1.24%
1,086
+336
+45% +$624K
IOVA icon
29
Iovance Biotherapeutics
IOVA
$3.74B
$2.3M 1.21%
280,000
+20,000
+8% +$169K
CORI
30
DELISTED
Corium International, Inc.
CORI
$2.25M 1.18%
400,000
+40,000
+11% +$201K
AMRN
31
Amarin Corp
AMRN
$297M
$2.23M 1.17%
35,000
-53,000
-60% -$2.97M
NDRM
32
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.82M 0.95%
98,500
+46,000
+88% +$797K
NBRV
33
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.69M 0.88%
958
-122
-11% -$235K
INNL
34
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.56M 0.82%
269,100
+4,100
+2% +$23.2K
AFMD
35
DELISTED
Affimed
AFMD
$1.2M 0.63%
43,000
-16,500
-28% -$463K
INDP icon
36
Indaptus Therapeutics
INDP
$155M
$1.03M 0.54%
78
-212
-73% -$2.64M
TENX icon
37
Tenax Therapeutics
TENX
$82M
$905K 0.47%
12
-3
-20% -$237K
PTLA
38
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$795K 0.42%
+35,000
New +$822K
ABEO icon
39
Abeona Therapeutics
ABEO
$345M
$600K 0.31%
+4,000
New +$391K
AMAG
40
DELISTED
AMAG Pharmaceuticals
AMAG
$368K 0.19%
15,000
-105,000
-88% -$2.62M
BLRX
41
BioLineRX
BLRX
$12.1M
$288K 0.15%
417
– –
ASRT
42
DELISTED
Assertio
ASRT
$41K 0.02%
+28
New +$35.2K
ADAP
43
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-40,000
Closed -$326K
CDTX
44
DELISTED
Cidara Therapeutics
CDTX
– –
-2,150
Closed -$443K
EVOK
45
DELISTED
Evoke Pharma
EVOK
– –
-903
Closed -$891K
MCRB icon
46
Seres Therapeutics
MCRB
$49.7M
– –
-2,875
Closed -$1.67M
OCUL icon
47
Ocular Therapeutix
OCUL
$2.38B
– –
-260,000
Closed -$1.29M
SUPN icon
48
Supernus Pharmaceuticals
SUPN
$2.57B
– –
-125,000
Closed -$2.55M
TGTX icon
49
TG Therapeutics
TGTX
$8.53B
– –
-175,000
Closed -$1.06M
TNXP icon
50
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– -$1.59M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opaleye Management held 54 positions worth $191M, up 28% from $150M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Opaleye Management's Q3 2016 filing shows 5 new, 14 increased, 20 reduced and 9 closed positions. Its largest new stake was Loxo Oncology, Inc: 110,000 shares worth $2.88M. The largest sale was Amarin Corp, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2016 buy was Loxo Oncology, Inc: 110,000 shares worth $2.88M.
  • Opaleye Management added most to Blueprint Medicines in Q3 2016, an estimated $13.3M increase.
  • Opaleye Management's biggest Q3 2016 reduction was Amarin Corp, cutting an estimated $2.97M.
  • Opaleye Management fully exited Supernus Pharmaceuticals in Q3 2016, selling an estimated $2.55M.
  • Opaleye Management's ten largest holdings make up 53% of its $191M portfolio in Q3 2016.
  • Opaleye Management opened 5 new positions and closed 9 in Q3 2016.
  • Opaleye Management's portfolio value rose 28% quarter-over-quarter to $191M.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.